{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Resistant+Solid+Malignancies&page=5",
    "query": {
      "condition": "Resistant Solid Malignancies",
      "page": 5
    },
    "page_size": 10
  },
  "pagination": {
    "page": 5,
    "page_size": 10,
    "total_count": 189,
    "total_pages": 19,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Resistant+Solid+Malignancies&page=6&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Resistant+Solid+Malignancies&page=4&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-15T11:26:07.033Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02898207",
      "title": "Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic High Grade Fallopian Tube Serous Adenocarcinoma",
        "Metastatic Malignant Solid Neoplasm",
        "Metastatic Primary Peritoneal Serous Adenocarcinoma",
        "Metastatic Triple-Negative Breast Carcinoma",
        "Platinum-Resistant Fallopian Tube Carcinoma",
        "Platinum-Resistant Ovarian Carcinoma",
        "Platinum-Resistant Primary Peritoneal Carcinoma",
        "Recurrent Breast Carcinoma",
        "Recurrent High Grade Fallopian Tube Serous Adenocarcinoma",
        "Recurrent High Grade Ovarian Serous Adenocarcinoma",
        "Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma",
        "Recurrent Triple-Negative Breast Carcinoma",
        "Refractory Fallopian Tube Serous Adenocarcinoma",
        "Refractory Ovarian Serous Adenocarcinoma",
        "Refractory Primary Peritoneal Serous Adenocarcinoma",
        "Refractory Triple-Negative Breast Carcinoma",
        "Unresectable High Grade Fallopian Tube Serous Adenocarcinoma",
        "Unresectable Malignant Solid Neoplasm",
        "Unresectable Primary Peritoneal Serous Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Olaparib",
          "type": "DRUG"
        },
        {
          "name": "Onalespib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 28,
      "start_date": "2017-05-19",
      "completion_date": "2022-01-14",
      "has_results": true,
      "last_update_posted_date": "2023-04-26",
      "last_synced_at": "2026-11-15T11:26:07.033Z",
      "location_count": 8,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Jacksonville, Florida + 2 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02898207"
    },
    {
      "nct_id": "NCT05023993",
      "title": "The Effect of Exercise and Nicotinamide Riboside Muscle Health and Insulin Resistance in Survivors of Childhood Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Hematopoietic and Lymphoid Cell Neoplasm",
        "Malignant Solid Neoplasm",
        "Prediabetes"
      ],
      "interventions": [
        {
          "name": "Exercise Intervention",
          "type": "OTHER"
        },
        {
          "name": "Nicotinamide Riboside",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2022-10-27",
      "completion_date": "2027-09-07",
      "has_results": false,
      "last_update_posted_date": "2026-10-30",
      "last_synced_at": "2026-11-15T11:26:07.033Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05023993"
    },
    {
      "nct_id": "NCT04901806",
      "title": "Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor, Adult",
        "Brain Tumor, Primary",
        "Desmoplastic Small Round Cell Tumor"
      ],
      "interventions": [
        {
          "name": "PBI-200",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pyramid Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 29,
      "start_date": "2021-07-20",
      "completion_date": "2023-07-26",
      "has_results": false,
      "last_update_posted_date": "2024-03-28",
      "last_synced_at": "2026-11-15T11:26:07.033Z",
      "location_count": 11,
      "location_summary": "Santa Monica, California • Stanford, California • Denver, Colorado + 7 more",
      "locations": [
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Lake Mary",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04901806"
    },
    {
      "nct_id": "NCT05888532",
      "title": "64Cu-GRIP B in Patients With Advanced Malignancies",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer",
        "Renal Cancer",
        "Urethral Cancer",
        "Advanced Solid Tumor",
        "Metastatic Castration-resistant Prostate Cancer",
        "Solid Tumor, Adult"
      ],
      "interventions": [
        {
          "name": "Copper-64 labeled Granzyme B (64Cu-GRIP B)",
          "type": "DRUG"
        },
        {
          "name": "Positron Emission Tomography (PET)",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Rahul Aggarwal",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 91,
      "start_date": "2023-05-25",
      "completion_date": "2027-01-31",
      "has_results": false,
      "last_update_posted_date": "2026-03-17",
      "last_synced_at": "2026-11-15T11:26:07.033Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05888532"
    },
    {
      "nct_id": "NCT06939283",
      "title": "A Phase 1b/2 Multisite Dose-finding and Expansion Study of WTX-330 in Adult Patients With Selected Advanced or Metastatic Solid Tumors or Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced or Metastatic Solid Tumors",
        "Non-Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "WTX-330",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Werewolf Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2025-04-21",
      "completion_date": "2026-04-23",
      "has_results": false,
      "last_update_posted_date": "2026-10-19",
      "last_synced_at": "2026-11-15T11:26:07.033Z",
      "location_count": 5,
      "location_summary": "Scottsdale, Arizona • Atlanta, Georgia • Chicago, Illinois + 2 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06939283"
    },
    {
      "nct_id": "NCT01540526",
      "title": "Pharmacodynamic Study With FLT-PET/CT in Patients With Prostate/Other Solid Malignancies Treated With High Dose Axitinib",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Malignancies",
        "Metastatic Castrate-resistant Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "axitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Wisconsin, Madison",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2012-03",
      "completion_date": "2014-12",
      "has_results": false,
      "last_update_posted_date": "2019-11-19",
      "last_synced_at": "2026-11-15T11:26:07.033Z",
      "location_count": 1,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01540526"
    },
    {
      "nct_id": "NCT05415098",
      "title": "Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Nasopharyngeal Carcinoma",
        "Castrate Resistant Prostate Cancer",
        "Gastric Cancer",
        "Ovarian Clear Cell Carcinoma",
        "Mesothelioma",
        "Sarcoma",
        "Non Hodgkin Lymphoma",
        "B Cell Lymphoma",
        "Epithelioid Sarcoma"
      ],
      "interventions": [
        {
          "name": "APG-5918",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ascentage Pharma Group Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 90,
      "start_date": "2022-09-30",
      "completion_date": "2025-09-30",
      "has_results": false,
      "last_update_posted_date": "2022-11-16",
      "last_synced_at": "2026-11-15T11:26:07.033Z",
      "location_count": 1,
      "location_summary": "Springdale, Arkansas",
      "locations": [
        {
          "city": "Springdale",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05415098"
    },
    {
      "nct_id": "NCT03449108",
      "title": "LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Bone Sarcoma",
        "Dedifferentiated Chondrosarcoma",
        "Giant Cell Tumor of Bone",
        "Malignancy in Giant Cell Tumor of Bone",
        "Malignant Solid Neoplasm",
        "Ovarian Carcinosarcoma",
        "Platinum-Resistant Ovarian Carcinoma",
        "Poorly Differentiated Thyroid Gland Carcinoma",
        "Recurrent Osteosarcoma",
        "Recurrent Ovarian Carcinoma",
        "Refractory Osteosarcoma",
        "Soft Tissue Sarcoma",
        "Thyroid Gland Anaplastic Carcinoma",
        "Thyroid Gland Squamous Cell Carcinoma",
        "Undifferentiated High Grade Pleomorphic Sarcoma of Bone",
        "Triple Negative Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Aldesleukin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Autologous Tumor Infiltrating Lymphocytes LN-145",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Autologous Tumor Infiltrating Lymphocytes LN-145-S1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "16 Years to 70 Years"
      },
      "enrollment_count": 30,
      "start_date": "2018-04-27",
      "completion_date": "2027-04-30",
      "has_results": false,
      "last_update_posted_date": "2026-11-10",
      "last_synced_at": "2026-11-15T11:26:07.033Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03449108"
    },
    {
      "nct_id": "NCT01884285",
      "title": "AZD8186 First Time In Patient Ascending Dose Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Castrate-resistant Prostate Cancer CRPC",
        "Squamous Non-Small Cell Lung Cancer sqNSCLC",
        "Triple Negative Breast Cancer TNBC"
      ],
      "interventions": [
        {
          "name": "Part A: AZD8186 monotherapy",
          "type": "DRUG"
        },
        {
          "name": "Part B: AZD8186 monotherapy",
          "type": "DRUG"
        },
        {
          "name": "Part C1: Abiraterone acetate combination with AZD8186",
          "type": "DRUG"
        },
        {
          "name": "Part D1: AZD2014 combination with AZD8186",
          "type": "DRUG"
        },
        {
          "name": "Part D2 AZD2014 combination with AZD8186",
          "type": "DRUG"
        },
        {
          "name": "Part C2: Abiraterone acetate combination with AZD8186",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 147,
      "start_date": "2013-07-09",
      "completion_date": "2020-02-07",
      "has_results": false,
      "last_update_posted_date": "2020-05-29",
      "last_synced_at": "2026-11-15T11:26:07.033Z",
      "location_count": 5,
      "location_summary": "Boston, Massachusetts • Detroit, Michigan • New York, New York + 2 more",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01884285"
    },
    {
      "nct_id": "NCT06421935",
      "title": "M9466 Alone or in Combination in Advanced Solid Tumors (DDriver 501)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumor"
      ],
      "interventions": [
        {
          "name": "M9466",
          "type": "DRUG"
        },
        {
          "name": "Tuvusertib",
          "type": "DRUG"
        },
        {
          "name": "Abiraterone acetate",
          "type": "DRUG"
        },
        {
          "name": "Prednisone/Prednisolone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "EMD Serono Research & Development Institute, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2024-08-07",
      "completion_date": "2027-02-22",
      "has_results": false,
      "last_update_posted_date": "2026-09-09",
      "last_synced_at": "2026-11-15T11:26:07.033Z",
      "location_count": 2,
      "location_summary": "New York, New York • Houston, Texas",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06421935"
    }
  ]
}